RET and non-small cell lung carcinoma: In this regard, both RET-selective TKIs, BLU-667 and LOXO-292 have demonstrated preliminary encouraging CNS activity in patients with advanced RET+ NSCLC and baseline brain metastases [19,23,25,35].